Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

2046 Results

Drug

crisantaspase recombinant

Other Name(s): Rylaze™

Quick Link(s): Drug Monograph, Patient Info Sheet

Jan 2024

Oncology Biosimilars Utilization Data

Statistical Reports

Ontario Cancer Screening Performance Report, 2023

Jan 2024

Document

OBSP-Patient-Information-Sheet

Nov 2023

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Document

obsp-11-23-23.xml

Nov 2023

Document

obsp-11-23-23.html

Nov 2023

Document

obsp-12-04-23.xml

Dec 2023

Document

obsp-12-04-23.html

Dec 2023

Document

CoP-Fall2023.pdf

Dec 2023

Document

obsp-12-13-23.xml

Dec 2023

Document

obsp-12-12-23.xml

Dec 2023

Pages